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Abstract 
Cancer is a chronic inflammatory state which is often associated with increased platelet 
counts. Cancer cells induce thrombopoiesis and activate platelets, which in turn facilitate 
cancer invasion and metastasis. In this study, we investigate the correlation between 
platelet counts with each of stage and overall survival in melanoma. This is a retrospective 
cohort study of 642 melanoma patients diagnosed or treated at a tertiary medical center 
between 2000 and 2016. Multivariable analysis adjusted for age, sex, stage and treatment 
modality. Using multivariable analysis, patients with thrombocytosis around time of 
diagnosis were more likely to present with distant metastasis (Prevalence Ratio 3.5, 95% 
CI 2.35-5.22). In patients with metastatic disease and in all stages combined, 
thrombocytosis predicted decreased 5-year overall survival in univariate and multivariable 
analysis, and this was most pronounced during the first year from diagnosis. Finally, we 
show that mice with thrombocytopenia due to the lack of heat shock protein gp96 in their 
megakaryocytes are protected from melanoma dissemination to the lungs. These findings 
are concordant with preclinical studies showing a role for platelets in cancer metastasis 
and suppression of antitumor immunity, further supporting targeting platelets as an 
adjuvant to immunotherapy in melanoma.  
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Introduction 
In addition to their role in hemostasis, platelets contain a myriad of bioactive molecules and 
contribute to inflammation, cancer invasion and metastasis. Tumor cells engage platelets in a 
process termed tumor cell-induced platelet aggregation (TCIPA), which aids the former in evading 
the immune system[1]. Cancer cell-derived thrombin is a mediator of this process and facilitates 
metastasis[2], and the ability of cancer cells to initiate TCIPA correlates with their metastatic 
potential[3]. Moreover, tumor-derived IL-6 induces thrombopoietin production by the liver, thus 
promoting thrombopoiesis[4], at least partially explaining the association between thrombocytosis 
and malignancy[5].  
When cancer cells leave the primary tumor and enter blood stream, they activate surrounding 
platelets via molecules such as HMB1[6] and ADP[7], inducing microthrombus formation. This in 
turn shields cancer cells from the immune attack by natural killer cells[7]. Mice with defective 
platelet function are protected from melanoma dissemination to their lungs; however, this 
protection is mitigated by depletion of natural killer cells[8]. Platelets also propagate tumor cell 
metastasis independent of natural killer cells[9]. CD97 on cancer cells activates platelets to 
release lysophosphatidic acid (LPA), thus facilitating trans-endothelial migration[10]. We have 
also shown that platelets activate TGFβ and suppress anti-tumor T lymphocytes, thus aiding in 
melanoma growth[11]. Platelet-derived TGFβ also acts directly on cancer cells inducing epithelial-
mesenchymal transition, thus increasing their metastatic potential[12]. Moreover, platelets 
secrete CXCL5 and CXCL7 which recruit granulocytes to cancer cells, leading to the formation of 
early metastatic niches[13].  
In recent work, we showed that aspirin use after diagnosis correlated with longer survival in 
advanced stages of melanoma. We also observed that aspirin intake prior to diagnosis correlated 
with earlier stages[14]. In addition, increased levels of circulating platelet-derived microparticles 
are associated with metastatic cutaneous melanoma[15]. Increased platelet counts have also 
been associated with worse outcomes in other cancer types[16, 17, 18]. In light of this evidence, 
we investigate here the association between platelet count and stage of melanoma, as well as 
the prognostic value of platelet count. 
Methods 
Study design 
This study was approved by the institutional review board (IRB) at Indiana University (IU). We 
obtained demographic and cancer-related data from the Simon Comprehensive Cancer Center 
registry at IU. Data are collected by the registry from pathology reports, electronic medical 
records, radiation and chemotherapy oncology reports, and coding and billing data. Patients in 
this study were diagnosed between January 1st, 2000 and December 31st, 2014, and followed-up 
through September, 2016. Patients with platelet counts obtained within 3 months from date of 
diagnosis and prior to any systemic treatment, and with complete TNM staging were included in 
our analysis. The vast majority (99%) of the patients were Caucasian. Our analysis was thus 
limited to Caucasian patients since the small number of other racial groups limits the 
generalizability of our findings to non-Caucasian patients, and prohibits adjusting for race in multi-
variable analysis. However, we performed sensitivity analyses to demonstrate that including other 
racial groups does not change our findings. Overall survival was calculated as the interval from 
the time of diagnosis to date of last contact, and survival times for patients alive at time of last 
contact were censored. For each patient, we obtained data on platelet counts from the IU Clinical 
Data Warehouse (CDW). Thrombocytosis was defined as platelet count >350x103/µL. 
Data analysis 
Descriptive statistics were used to summarize continuous and discrete variables. Continuous 
variables were compared using two-sided t-test and discrete variables were compared using the 
chi-square or two-sided Fisher’s exact test, depending on the pertinent sample size. All statistical 
analyses were done using Stata version 14.1. 
We used Kaplan-Meier plots to visualize univariate survival after melanoma diagnosis by platelet 
count, and survival curves were compared statistically using log-rank tests. We estimated the 
association between platelet counts and melanoma survival as hazard ratios and 95% confidence 
intervals from Cox proportional hazards regression with time from diagnosis as the time metric. 
We examined the proportional hazards assumption using Schoenfeld residuals, visually using 
log-log survival plots, and by modeling interaction terms between platelet counts and time. We 
found evidence for non-proportionality in analysis of all stages combined and stage 4 melanoma, 
specifically occurring early after diagnosis, so we reported hazard ratios for 1-year survival and 
5-year survival, conditional on 1-year survival. 
We used log-binomial regression to estimate prevalence ratios and 95% confidence intervals 
between platelet count and stage. Our outcome of interest for stage was stage IV versus stage 
0-III. When log-binomial model failed to converge, we used Poisson regression with robust 
variance, which approximates the log-binomial estimates.  
Platelet counts were available in 40.5% of participants. Due to potential selection bias using only 
participants with platelet counts, we performed a sensitivity analysis, repeating all analyses using 
multiple imputation to account for missingness (Supplementary material). We assumed the 
platelet counts were missing at random and that missingness could be explained by variables in 
our dataset. We examined predictors of platelet count and missingness to determine the 
imputation model and decided upon using the following variables: age at diagnosis, stage, 
diabetes, hypertension, alcohol use, vital status, and time to death or censoring. We used multiple 
imputation with Markov Chain Monte Carlo (MCMC) procedures, assuming a multivariate normal 
distribution (MVN) and using 50 imputed datasets in Stata 14.1. The results after multiple 
imputation were qualitatively consistent with the multivariable adjusted complete case analysis. 
Results 
Baseline characteristics 
Platelet counts were available for 642 melanoma patients. Patients with thrombocytosis were 
slightly younger and females were over-represented in this group. They also presented in more 
advanced stages, and subsequently were less likely to receive surgery and more likely to be 
treated with chemotherapy. There was less involvement of the head and neck areas in patients 
with thrombocytosis, approaching statistical significance. No differences in cardiovascular 
comorbidities were observed between the two groups (Table 1). 
Thrombocytosis and distant metastasis 
Given the established role of platelets in mediating metastasis in preclinical studies, the 
association between platelet count around time of diagnosis and distant metastasis (Stage IV) 
was investigated. Patients with thrombocytosis presented with more advanced stages (Table 1). 
Specifically, they were more likely to present in stage IV in univariate analysis and after adjusting 
for age and sex (Prevalence Ratio 3.5 [95% CI 2.35-5.22], Table 2). Analyzing platelets as a 
continuous variable showed that for every 100-unit increase in platelet count, patients were 33% 
(95% CI 21-47%) more likely to present with distant metastasis (Table 2). This association 
between thrombocytosis and distant metastasis persisted after sensitivity analysis using multiple 
imputation to account for patients with missing platelet counts and after including non-white 
patients (Supp. Tables 1, 2). 
Platelets predict overall survival 
Patients with thrombocytosis experienced shorter overall 5-year survival (p=0.02, Figure 1). 
Importantly, this decreased 5-year survival was most pronounced during the first year after 
diagnosis (Figure 1). Given these non-proportional hazards, we estimated the prognostic 
significance of platelets separately in the first year, and between 1 and 5 years for those alive at 
1 year. 
Higher platelet counts predicted increased mortality at 1 year in all stages of melanoma combined. 
This was also observed after adjusting for age, sex, stage and treatment modality (Table 3). 
Patients were then stratified into those with versus without distant metastatic disease (stages 0-
III versus IV). Thrombocytosis predicted shorter survival in stage IV within the first year, but not 
in patients with localized/regional spread (stages 0-III, table 3). The same trend was observed 
when platelets were analyzed as a continuous variable, showing an incremental increase in 
mortality with each 100-unit increase of platelet counts. Among survivors at one year, platelet 
counts did not predict further survival in either metastatic or local/regional disease (Table 3). Upon 
performing sensitivity analysis to account for patients with no available platelet counts and to 
include the non-Caucasian population, similar associations were observed (Supp. Tables 3,4). 
Finally, further analysis of stages 0, I, II and III separately showed no predictive value of 
thrombocytosis; concordant with the pooled stage 0-III analysis (Supp. Table 5).    
Platelets promote melanoma dissemination to the lungs in mice 
To illustrate that targeting platelets is a viable option to prevent melanoma metastasis, we used 
a mouse model of thrombocytopenia[11]. The heat shock protein gp96 (HSP90b1) was selectively 
deleted from megakaryocytes in PF4-Cre Hsp90b1flox/flox mice (knockout; KO). The lack of gp96 
in megakaryocytes resulted in ineffective thrombopoiesis and low platelet counts (Figure 2A). Wild 
type (WT) and KO mice were injected with B16 melanoma cells via the lateral tail vein. Ten days 
later, KO mice had significantly fewer melanoma tumors in their lungs compared to their WT 
littermates (Figure 2B).  
 
 
Discussion 
In this study, we observed that thrombocytosis is associated with melanoma distant metastasis 
and shorter overall survival. Within stage IV, higher platelet counts correlated with shorter survival 
in the first year in univariate analysis and after adjusting for age, sex, and treatment. These 
observations were consistent in sensitivity analyses to account for non-white patients and those 
with missing platelet counts. We used a mouse model of thrombocytopenia to show that targeting 
platelets protects against melanoma dissemination to the lungs. These data suggest that platelets 
could serve as a prognostic biomarker in patients with advanced melanoma, and that targeting 
this cellular entity can have a therapeutic role. It is worth mentioning that mortality from stage IV 
melanoma, especially prior to the institution of immunotherapy as a first line treatment, occurred 
largely in the first year after diagnosis, which likely explains the prognostic significance of platelets 
mainly in the first year, but not beyond. 
The worse outcomes and more advanced stage associated with thrombocytosis is likely a product 
of two factors: Increased number of platelets propagates cancer dissemination and immune 
evasion, and intrinsically more aggressive cancers can incite systemic inflammation and induction 
of thrombopoiesis. This proposed bidirectional relationship is supported by evidence from 
preclinical studies as described in the introduction. Cancer is a chronic inflammatory state which 
often leads to secondary increase in thrombopoiesis due to inflammation or co-existent anemia 
of chronic disease, and platelets are in turn sabotaged in favor of the ongoing malignancy. In 
addition to their numbers, platelets are qualitatively altered in cancer patients, and were found to 
harbor tumor-derived RNA[19].  A recent study showed that increased platelet-to-lymphocyte ratio 
correlates with worse outcomes in melanoma, but did not independently evaluate the significance 
of platelet counts [20]. The study also was limited by a small sample size and not defining the cut-
off value a priori. This cut-off was not validated in an independent patient cohort, which raises the 
concern about false positive observations.  
In this study, platelet counts were not available for all patients. It is conceivable that patients with 
more advanced stages are more likely to get blood tests including platelet counts as part of their 
work up. Indeed, around 70% of our patient population had Breslow thickness > 1 mm, which is 
an over-representation. This is because blood counts are not part of the standard work up for thin 
melanomas. This limits the generalizability of our conclusions due to spectrum selection bias. To 
address that, we performed multiple imputation sensitivity analysis accounting for patients with 
no available platelet counts, and similar conclusions were obtained (Supp. Tables 1 and 3). Given 
that cardiovascular disease is the leading cause of death in the US population and the role of 
platelets in cardiovascular disease, we compared cardiovascular comorbidities across the two 
patient populations; there was no increase in cardiovascular comorbidities in patients with 
thrombocytosis (Table 1). 
In a recent study, temporal measurement of platelet counts between four years prior to diagnosis 
and the time of treatment was used to predict outcomes in lung, prostate and colon cancers[21]. 
Adding platelet count features such as frequency of measurements among several other features 
increased the predictive value by 20-30% compared to post-diagnosis thrombocytosis alone. This 
study suggests a useful method of predicting outcomes, and provides deeper insight to the 
significance of platelets during the period of preclinical malignant transformation. Its applicability 
to everyday clinical practice has yet to be proven. The study was conducted on Veterans Affairs 
patients who mostly have their care in one centralized healthcare system. In contrast, non-veteran 
patients often seek medical care in different hospitals and outpatient settings, and are often 
referred to larger care centers for work up and management of their cancers. Hence, obtaining 
retrospective data on platelet counts can prove challenging. Nevertheless, the study is 
conceptually novel and with the aid of softwares tailored to capture platelet count features, such 
model could prove useful.  
In mouse models, we previously uncovered that platelets suppress anti-melanoma T cell immunity 
partly by activating TGFβ[11]. Additionally, in the current study, we show that genetically targeting 
platelets in mice protects against melanoma dissemination to the lungs. In a separate clinical 
study, we observed that intake of aspirin correlated with longer overall survival in melanoma, 
particularly in stages II-IV[14]. Hence, targeting platelets is a promising adjuvant therapeutic 
approach in melanoma and cancer in general. Indeed, clinical trials are currently underway, 
combining platelet inhibitors such as aspirin and clopidogrel with immunotherapy in metastatic 
melanoma and head and neck carcinoma (NCT03396952 and NCT03245489).  
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Figures 
Figure 1. Overall survival in stages 0-IV melanoma. 5-year survival from the time of 
diagnosis in melanoma patients of all stages (0-IV). N=642, Log rank p=0.02. 
Figure 2. Platelet-specific knockout of gp96 results in thrombocytopenia and protection 
from melanoma lung colonization. A. Knockout mice were bled from the lateral tail vein to 
measure platelet counts. B. Mice were injected with 1x105 B16 melanoma cells in the lateral tail 
vein and mice were sacrificed 10 days later. Error bars represent standard error of the mean. 
Two-tailed independent Student t-test was used to compare the two groups. 
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Table 1. Demographic and clinical characteristics of study population with platelet counts 
(N=642) 
Variable Overall Platelet count 
<350 
Platelet count 
≥350 
P value 
Mean age (SD), years 57.7 (16.1) 58.1 (16.3) 53.0 (13.4) 0.03 
Female, N (%) 270 (42.1) 237 (40.2) 33 (63.5) 0.001 
Stage, N (%) 
   In situ 
   Stage I 
   Stage II 
   Stage III 
   Stage IV 
 
154 (24.0) 
158 (24.6) 
83 (12.9) 
159 (24.8) 
88 (13.7) 
 
145 (24.6) 
148 (25.1) 
79 (13.4) 
148 (25.1) 
70 (11.9) 
 
9 (17.3) 
10 (19.2) 
4 (7.7) 
11 (21.2) 
18 (34.6) 
<0.001 
Anatomical site, N (%) 
Head/neck 
Trunk 
Extremities 
Other 
 
146 (22.7) 
175 (27.3) 
247 (38.5) 
74 (11.5) 
 
139 (23.6) 
163 (27.6) 
225 (38.1) 
63 (10.7) 
 
7 (13.5) 
12 (23.1) 
22 (42.3) 
11 (21.2) 
0.06 
Diabetes mellitus, N (%) 108 (16.8) 102 (17.3) 6 (11.5) 0.29 
Hypertension, N (%) 225 (35.0) 211 (35.8) 14 (26.9) 0.20 
Dyslipidemia, N (%) 189 (29.4) 177 (30.0) 12 (23.1) 0.29 
Cardiovascular disease, N (%) 76 (11.8) 73 (12.4) 3 (5.8) 0.16 
Surgery, N (%) 563 (87.7) 528 (89.5) 35 (67.3) <0.001 
Chemotherapy, N (%) 45 (7.1) 37 (6.3) 8 (15.4) 0.02 
Radiation, N (%) 49 (7.6) 45 (7.6) 4 (7.7) 0.99 
Immunotherapy, N (%) 73 (11.4) 70 (11.9) 3 (5.8) 0.18 
Breslow thickness ≥1mm, N 
(%) 
236 (69.2) 219 (69.1) 17 (70.8) 0.86 
Fisher’s exact tests were used in place of Chi-square test when cell sizes were <10.  
 
Table 2. Prevalence ratios and 95% confidence intervals for association between platelet counts 
and stage IV melanoma (versus stage 0-III, N=642) 
Exposure Platelets ≥350 Plateletsb 
 PR (95% CI) P PR (95% CI) P 
Unadjusted 2.92 (1.89, 4.50) <0.001 1.37 (1.26, 1.50) <0.001 
Adjusteda 3.50 (2.35, 5.22) <0.001 1.33 (1.21, 1.47) <0.001 
aAdjusted for age and sex 
bPlatelets as a continuous variable was modeled for a 100-unit increase 
 
Table 3. Hazard ratios and 95% confidence intervals for platelet counts and survival in 
melanoma. 
Exposure Platelets ≥350 Plateletsc 
 HR (95% CI) P HR (95% CI) P 
1-year survival 
All stages combined (N=642) 
Unadjusted 3.24 (1.84, 5.69) <0.001 1.52 (1.33, 1.72) <0.001 
Adjusteda 1.92 (1.08, 3.43) 0.03 1.29 (1.13, 1.48) <0.001 
Stages 0-III (N=554) 
Unadjusted 0.85 (0.11, 6.39) 0.88 1.31 (0.72, 2.38) 0.38 
Adjusteda 1.18 (0.15, 9.03) 0.87 1.63 (0.89, 3.00) 0.12 
Stage IV (N=88) 
Unadjusted 1.74 (0.95, 3.17) 0.07 1.14 (0.99, 1.30) 0.05 
Adjustedb 1.80 (0.97, 3.34) 0.06 1.20 (1.04, 1.40) 0.01 
 
5-year survival in patients alive at 1 year 
All stages combined (N=553) 
Unadjusted 0.63 (0.23, 1.73) 0.37 0.84 (0.62, 1.15) 0.28 
Adjusteda 0.45 (0.16, 1.25) 0.13 0.85 (0.62, 1.16) 0.31 
Stages 0-III (N=523) 
Unadjusted 0.62 (0.20, 1.98) 0.42 0.81 (0.57, 1.15) 0.24 
Adjusteda 0.99 (0.30, 3.24) 0.98 1.05 (0.71, 1.56) 0.81 
Stage IV (N=30) 
Unadjusted 0.34 (0.04, 2.56) 0.29 0.82 (0.46, 1.45) 0.49 
Adjustedb 0.30 (0.04, 2.34) 0.25 0.74 (0.41, 1.34) 0.33 
 
aAdjusted for continuous age, sex, treatment type and stage 
bAdjusted for continuous age, sex and treatment type 
cPlatelets as a continuous variable was modeled for a 100-unit increase 
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Table S1. Sensitivity analysis of prevalence ratios and 95% confidence intervals for association 
between platelet count and stage IV melanoma (versus stages 0-III) using multiple imputation to 
replace missing platelet counts 
Exposure Platelets ≥350 Plateletsb 
 PR (95% CI) P PR (95% CI) P 
Unadjusted 1.95 (1.17, 3.24) 0.01 1.37 (1.21, 1.55) <0.001 
Adjusteda 2.41 (1.43, 4.09) 0.001 1.39 (1.25, 1.55) <0.001 
aAdjusted for age and sex 
bPlatelets as a continuous variable was modeled for a 100-unit increase 
 
Table S2. Sensitivity analysis of prevalence ratios and 95% confidence intervals for association 
between platelet count and stage IV melanoma (versus stages 0-III) including non-Caucasian 
patients (N=655) 
Exposure Platelets ≥350 Plateletsb 
 PR (95% CI) P PR (95% CI) P 
Unadjusted 2.80 (1.82, 4.32) <0.001 1.37 (1.25, 1.49) <0.001 
Adjusteda 3.29 (2.19, 4.94) <0.001 1.33 (1.21, 1.46) <0.001 
aAdjusted for age and sex 
bPlatelets as a continuous variable was modeled for a 100-unit increase 
 
Table S3. Sensitivity analysis of hazard ratios and 95% confidence intervals for platelet count 
and survival using multiple imputation to replace missing platelet counts 
 
Exposure Platelets ≥350 Plateletsc 
 HR (95% CI) P HR (95% CI) P 
1-year survival 
All stages combined 
Unadjusted 1.85 (0.99, 3.45) 0.05 1.44 (1.21, 1.72) <0.001 
Adjusteda 1.68 (0.94, 3.00) 0.08 1.31 (1.13, 1.50) <0.001 
Stages 0-III 
Unadjusted 0.74 (0.12, 4.39) 0.74 1.04 (0.62, 1.74) 0.88 
Adjusteda 1.04 (0.17, 6.34) 0.97 1.31 (0.80, 2.17) 0.28 
Stage IV 
Unadjusted 1.47 (0.79, 2.73) 0.22 1.14 (0.99, 1.31) 0.06 
Adjustedb 1.55 (0.82, 2.91) 0.18 1.21 (1.04, 1.42) 0.02 
 
5-year survival in patients alive at 1 year 
All stages combined 
Unadjusted 0.79 (0.39, 1.61) 0.51 0.91 (0.70, 1.18) 0.49 
Adjusteda 0.80 (0.38, 1.69) 0.56 0.98 (0.74, 1.28) 0.87 
Stages 0-III 
Unadjusted 0.77 (0.34, 1.71) 0.52 0.89 (0.67, 1.18) 0.42 
Adjusteda 1.12 (0.49, 2.58) 0.79 1.14 (0.86, 1.51) 0.35 
Stage IV 
Unadjusted 0.55 (0.11, 2.90) 0.48 0.91 (0.54, 1.54) 0.72 
Adjustedb 0.53 (0.10, 2.82) 0.46 0.86 (0.50, 1.48) 0.59 
 
aAdjusted for continuous age, sex, treatment type and stage 
bAdjusted for continuous age, sex and treatment type 
cPlatelets as a continuous variable was modeled for a 100-unit increase 
 
Table S4. Sensitivity analysis of platelet count and survival including non-Caucasian patients 
(N=655) 
 
Exposure Platelets ≥350 Plateletsb 
 HR (95% CI) P HR (95% CI) P 
1-year survival 
Unadjusted 3.34 (1.93, 5.78) <0.001 1.52 (1.34, 1.72) <0.001 
Adjusteda 2.03 (1.15, 3.56) 0.001 1.28 (1.12, 1.46) <0.001 
     
5-year survival conditional on 1-year survival 
Unadjusted 0.64 (0.23, 1.76) 0.39 0.84 (0.61, 1.14) 0.27 
Adjusteda 0.45 (0.16, 1.27) 0.13 0.84 (0.61, 1.15) 0.27 
 
aAdjusted for continuous age, sex, treatment type and stage 
bPlatelets as a continuous variable was modeled for a 100-unit increase 
 
 
Table S5. Hazard ratios and 95% confidence intervals for platelet count and survival stratified by 
stage.  
 
Exposure Platelets ≥350 
 HR (95% CI) P 
Stage 0 (N=154), 5-year survivala 
Unadjusted 1.20 (0.16, 9.22) 0.86 
Adjustedb 2.40 (0.27, 21.13) 0.43 
Stage I (N=158), 5-year survivala 
Unadjusted 0.90 (0.12, 6.90) 0.92 
Adjustedb 1.59 (0.19, 13.18) 0.67 
Stage II (N=83), 5-year survivalc 
Unadjusted - - 
Adjusted - - 
Stage III  
1-year survival (N=159) 
Unadjusted 1.77 (0.22, 14.19) 0.59 
Adjustedd 1.95 (0.23, 16.68) 0.54 
5-year survival in patients alive at 1 year (N=148) 
Unadjusted 0.43 (0.06, 3.14) 0.40 
Adjustedd 0.60 (0.08, 4.69) 0.63 
Stage IV 
1-year survival (N=88) 
Unadjusted 1.74 (0.95, 3.17) 0.07 
Adjustedd 1.80 (0.97, 3.34) 0.06 
5-year survival in patients alive at 1 year (N=30) 
Unadjusted 0.34 (0.04, 2.56) 0.29 
Adjustedd 0.30 (0.04, 2.34) 0.25 
 
aNot enough events in the first year in stages 0-II to split analysis at 1 year 
bAdjusted for continuous age and sex. Patients uniformly treated surgically 
cOnly 4 patients in thrombocytosis group, none dead. Hence, survival analysis not possible 
dAdjusted for continuous age, sex and treatment. 
 
